DCM
BHVN icon

Defilade Capital Management’s Biohaven BHVN Stock Holding History

Defilade Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-315,944
Closed -$2.67M – 42
2026
Q1 		$2.67M Buy
+315,944
New +$3.46M 0.38% 30

Other funds holding BHVN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Defilade Capital Management's BHVN Position: Q2 2026 in Review

Defilade Capital Management sold out of Biohaven (BHVN) in Q2 2026, closing a stake of 315,944 shares — an estimated $2.67M sold.

Defilade Capital Management first reported a position in BHVN in Q1 2026 and held it in 1 quarter. The position peaked at $2.67M in Q1 2026. 292 funds tracked by Wall St. Rank hold BHVN as of Q2 2026.

  • Defilade Capital Management reported no remaining Biohaven position as of Q2 2026 after selling out during the quarter.
  • Defilade Capital Management sold 315,944 Biohaven shares in Q2 2026, an estimated $2.67M.
  • Defilade Capital Management first reported a position in Biohaven in Q1 2026 and held it in 1 quarter.
  • Defilade Capital Management's Biohaven position peaked at $2.67M in Q1 2026.
  • 292 funds tracked by Wall St. Rank held Biohaven as of Q2 2026.

Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.